Validation
The aim of this work package is to evaluate the imaging results obtained with the new agents and various technologies in comparison with those obtained using GBCAs.
Task 4.1: Validation of HP water as a competent perfusion agent
We will compare imaging results obtained with HP water to Gd-enhanced MRI in a pig model of coronary artery disease.
Task 4.2: Validation of HP 15N imaging
We will compare imaging results obtained with HP 15N to Gd-enhanced MRI. Perfusion imaging will be carried out in healthy rats (HMO) and in animal models of cardiovascular disease in rodents (UOXF). Tissue-retention imaging will be carried out in mice and rats bearing patient-derived xenografts and in genetically engineered tumour models (UCAM). Specifically for [15N2]urea, the imaging results will be also compared to imaging results with HP [13C]urea.
Task 4.3: In vivo imaging of PHIP-SAH polarised agents
Perfusion imaging will be investigated using the selected PHIP-SAH HP agent in mice bearing xenograft tumours and compared to Gd-enhanced MRI.
Task 4.4: In vivo imaging using optically HP nano-diamonds
Perfusion imaging using HP agents obtained by polarisation transfer from optically driven HP nano-diamonds will be investigated in healthy rodents and compared to Gd-enhanced MRI.
Task 4.5: In vivo imaging using dDNP HP nano-diamonds
Perfusion imaging using HP agents obtained by polarisation transfer from dDNP driven HP nano-diamonds will be investigated in healthy rodents and compared to Gd-enhanced MRI.